Teladoc Health, Inc. (4LL.F)
EUR 6.4
(6.36%)
EUR 6.4
(6.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 153.99 Million USD | -98.57% |
| 2022 | -13.37 Billion USD | 94428.21% |
| 2021 | -83.89 Million USD | 95.8% |
| 2020 | -437.95 Million USD | -1078.03% |
| 2019 | -35.14 Million USD | 4.91% |
| 2018 | -35.25 Million USD | 29.56% |
| 2017 | -70.42 Million USD | 9.13% |
| 2016 | -62.84 Million USD | 6.85% |
| 2015 | -50.92 Million USD | -296.9% |
| 2014 | -12.83 Million USD | -150.83% |
| 2013 | -5.11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 37 Million USD | -66.99% |
| 2024 Q2 | 62.67 Million USD | -2805.57% |
| 2023 Q1 | 24.51 Million USD | -99.36% |
| 2023 Q3 | 49.81 Million USD | 59.94% |
| 2023 Q2 | 31.14 Million USD | 27.07% |
| 2023 FY | - USD | -98.57% |
| 2023 Q4 | 86.8 Million USD | 74.26% |
| 2022 FY | - USD | 94428.21% |
| 2022 Q4 | 3.82 Billion USD | 61140.48% |
| 2022 Q1 | -1.27 Million USD | -106.44% |
| 2022 Q2 | -1.96 Million USD | -54.56% |
| 2022 Q3 | -6.27 Million USD | -219.13% |
| 2021 Q1 | -20.27 Million USD | 94.38% |
| 2021 Q4 | 19.75 Million USD | 1381.89% |
| 2021 Q2 | -12.22 Million USD | 39.72% |
| 2021 Q3 | -1.54 Million USD | 87.39% |
| 2021 FY | - USD | 95.8% |
| 2020 Q3 | 18.6 Million USD | 216.63% |
| 2020 Q4 | -360.89 Million USD | -2040.1% |
| 2020 Q2 | 5.87 Million USD | 196.01% |
| 2020 FY | - USD | -1078.03% |
| 2020 Q1 | -6.11 Million USD | -89.8% |
| 2019 Q1 | -10.31 Million USD | -50.63% |
| 2019 Q3 | -6.53 Million USD | 34.73% |
| 2019 Q4 | -3.22 Million USD | 50.64% |
| 2019 FY | - USD | 4.91% |
| 2019 Q2 | -10 Million USD | 2.96% |
| 2018 Q4 | -6.84 Million USD | -16.55% |
| 2018 FY | - USD | 29.56% |
| 2018 Q3 | -5.87 Million USD | 29.83% |
| 2018 Q2 | -8.37 Million USD | 9.7% |
| 2018 Q1 | -9.27 Million USD | 36.51% |
| 2017 Q3 | -6.59 Million USD | 32.07% |
| 2017 Q2 | -9.71 Million USD | 20.37% |
| 2017 Q4 | -14.6 Million USD | -121.31% |
| 2017 FY | - USD | 9.13% |
| 2017 Q1 | -12.19 Million USD | -14.69% |
| 2016 Q2 | -12.9 Million USD | 2.29% |
| 2016 Q4 | -10.63 Million USD | 7.17% |
| 2016 FY | - USD | 6.85% |
| 2016 Q3 | -11.45 Million USD | 11.24% |
| 2016 Q1 | -13.2 Million USD | -3.18% |
| 2015 FY | - USD | -296.9% |
| 2015 Q4 | -12.8 Million USD | -15.27% |
| 2015 Q3 | -11.1 Million USD | 27.56% |
| 2015 Q2 | -15.32 Million USD | -31.12% |
| 2015 Q1 | -11.69 Million USD | -110.82% |
| 2014 FY | - USD | -150.83% |
| 2014 Q2 | -2.3 Million USD | -29.88% |
| 2014 Q3 | -3.2 Million USD | -39.19% |
| 2014 Q4 | -5.54 Million USD | -72.9% |
| 2014 Q1 | -1.77 Million USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| DocCheck AG | 9.38 Million EUR | -1541.343% |
| CompuGroup Medical SE & Co. KGaA | 215.84 Million EUR | 28.653% |
| MeVis Medical Solutions AG | 5.12 Million EUR | -2902.145% |
| Nexus AG | 53.43 Million EUR | -188.217% |